All-trans retinoic acid enhances cytotoxicity of CIK cells against human lung adenocarcinoma by upregulating MICA and IL-2 secretion
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
All-trans retinoic acid enhances cytotoxicity of CIK cells against human lung adenocarcinoma by upregulating MICA and IL-2 secretion
Authors
Keywords
-
Journal
Scientific Reports
Volume 7, Issue 1, Pages -
Publisher
Springer Nature
Online
2017-11-22
DOI
10.1038/s41598-017-16745-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Increase of CIK cell efficacy by upregulating cell surface MICA and inhibition of NKG2D ligand shedding in multiple myeloma
- (2016) Chidimma A. Nwangwu et al. HEMATOLOGICAL ONCOLOGY
- All-Trans Retinoic Acid Inhibits Human Colorectal Cancer Cells RKO Migration via Downregulating Myosin Light Chain Kinase Expression through MAPK Signaling Pathway
- (2016) Li Zuo et al. NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL
- All-trans retinoic acid inhibits proliferation, migration, invasion and induces differentiation of hepa1-6 cells through reversing EMT in vitro
- (2015) JIEJIE CUI et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Can the dual-functional capability of CIK cells be used to improve antitumor effects?
- (2013) Xiaomeng Wang et al. CELLULAR IMMUNOLOGY
- Adoptive immunotherapy for cancer
- (2013) Marco Ruella et al. IMMUNOLOGICAL REVIEWS
- The CIK cells stimulated with combination of IL-2 and IL-15 provide an improved cytotoxic capacity against human lung adenocarcinoma
- (2013) Chuanyu Wei et al. TUMOR BIOLOGY
- Role of NKG2D in cytokine-induced killer cells against multiple myeloma cells
- (2012) Xuzhang Lu et al. CANCER BIOLOGY & THERAPY
- Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer
- (2012) Liangrong Shi et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- CIK cells – current status, clinical perspectives and future prospects – the good news
- (2012) Kam M Hui EXPERT OPINION ON BIOLOGICAL THERAPY
- Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors
- (2012) Giulia Mesiano et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Cytokine Induced Killer Cells as Promising Immunotherapy for Solid Tumors
- (2012) Dario Sangiolo Journal of Cancer
- Regulation of immune cell function and differentiation by the NKG2D receptor
- (2011) Biljana Zafirova et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Cord blood-derived cytokine-induced killer cells biotherapy combined with second-line chemotherapy in the treatment of advanced solid malignancies
- (2011) Qi Niu et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Expression of MICA, MICB and NKG2D in human leukemic myelomonocytic and cervical cancer cells
- (2011) Benny Weiss-Steider et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Modulation of NKG2D-ligand Cell Surface Expression Enhances Immune Cell Therapy of Cancer
- (2011) Baocheng Huang et al. JOURNAL OF IMMUNOTHERAPY
- Cancer Statistics, 2010
- (2010) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Developments in clinical cell therapy
- (2010) David Stroncek et al. CYTOTHERAPY
- All Trans Retinoic Acid and Cancer
- (2010) Siddikuzzaman et al. IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY
- Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC)
- (2010) C. Hontscha et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial
- (2009) Paola Olioso et al. HEMATOLOGICAL ONCOLOGY
- Immune Therapy for Cancer
- (2008) Michael Dougan et al. Annual Review of Immunology
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started